COCOS trial: COrticosteroids for COVID-19-induced loss of Smell–protocol for a single-centred, double-blind, randomised, placebo-controlled trial
Introduction Hyposmia and anosmia are common in COVID-19. Most patients regain normal smell within 4 weeks, but severe loss of smell persists roughly in 20% after 2 months and may last up to a year or longer. These persistent smell disorders greatly influence daily life. It is hypothesised that COVI...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-08-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/12/8/e060416.full |